Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 19 studies | 34% ± 10% | |
brain | 18 studies | 43% ± 19% | |
peripheral blood | 17 studies | 39% ± 14% | |
eye | 11 studies | 35% ± 13% | |
intestine | 10 studies | 31% ± 14% | |
kidney | 8 studies | 29% ± 9% | |
liver | 6 studies | 41% ± 18% | |
lymph node | 5 studies | 34% ± 8% | |
breast | 5 studies | 34% ± 11% | |
pancreas | 4 studies | 42% ± 22% | |
bone marrow | 4 studies | 34% ± 11% | |
heart | 4 studies | 26% ± 5% | |
uterus | 4 studies | 45% ± 15% | |
prostate | 4 studies | 26% ± 7% | |
adipose | 4 studies | 36% ± 8% | |
placenta | 3 studies | 33% ± 3% | |
skin | 3 studies | 24% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 12773.17 | 459 / 459 | 100% | 34.84 | 1118 / 1118 |
prostate | 100% | 10849.51 | 245 / 245 | 100% | 26.62 | 502 / 502 |
esophagus | 100% | 9507.65 | 1444 / 1445 | 100% | 51.27 | 183 / 183 |
lung | 100% | 11163.34 | 578 / 578 | 100% | 30.53 | 1154 / 1155 |
thymus | 100% | 13936.58 | 653 / 653 | 100% | 30.11 | 604 / 605 |
ovary | 100% | 12223.72 | 180 / 180 | 100% | 26.60 | 429 / 430 |
uterus | 100% | 13029.13 | 170 / 170 | 100% | 31.94 | 457 / 459 |
pancreas | 100% | 7620.60 | 328 / 328 | 99% | 28.29 | 177 / 178 |
bladder | 100% | 9921.71 | 21 / 21 | 99% | 28.06 | 501 / 504 |
brain | 99% | 7958.52 | 2621 / 2642 | 100% | 30.75 | 705 / 705 |
skin | 100% | 10555.09 | 1809 / 1809 | 99% | 26.70 | 466 / 472 |
adrenal gland | 100% | 8086.70 | 258 / 258 | 99% | 20.02 | 227 / 230 |
stomach | 100% | 8567.75 | 359 / 359 | 98% | 29.62 | 280 / 286 |
intestine | 100% | 11009.59 | 966 / 966 | 97% | 27.22 | 512 / 527 |
kidney | 100% | 7052.71 | 89 / 89 | 97% | 20.65 | 873 / 901 |
liver | 100% | 5022.33 | 226 / 226 | 86% | 10.80 | 351 / 406 |
adipose | 100% | 11156.12 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 10095.07 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 30.94 | 29 / 29 |
spleen | 100% | 12216.34 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 26.49 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 16.81 | 1 / 1 |
muscle | 100% | 6300.51 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 5172.95 | 841 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 85% | 15.23 | 68 / 80 |
peripheral blood | 71% | 4748.82 | 662 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0008380 | Biological process | RNA splicing |
GO_0006397 | Biological process | mRNA processing |
GO_0000381 | Biological process | regulation of alternative mRNA splicing, via spliceosome |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0005515 | Molecular function | protein binding |
GO_0003729 | Molecular function | mRNA binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | RBM25 |
Protein name | Alternative protein RBM25 RNA binding motif protein 25 RNA-binding protein 25 (Arg/Glu/Asp-rich protein of 120 kDa) (RED120) (Protein S164) (RNA-binding motif protein 25) (RNA-binding region-containing protein 7) |
Synonyms | RNPC7 |
Description | FUNCTION: RNA-binding protein that acts as a regulator of alternative pre-mRNA splicing. Involved in apoptotic cell death through the regulation of the apoptotic factor BCL2L1 isoform expression. Modulates the ratio of proapoptotic BCL2L1 isoform S to antiapoptotic BCL2L1 isoform L mRNA expression. When overexpressed, stimulates proapoptotic BCL2L1 isoform S 5'-splice site (5'-ss) selection, whereas its depletion caused the accumulation of antiapoptotic BCL2L1 isoform L. Promotes BCL2L1 isoform S 5'-ss usage through the 5'-CGGGCA-3' RNA sequence. Its association with LUC7L3 promotes U1 snRNP binding to a weak 5' ss in a 5'-CGGGCA-3'-dependent manner. Binds to the exonic splicing enhancer 5'-CGGGCA-3' RNA sequence located within exon 2 of the BCL2L1 pre-mRNA. Also involved in the generation of an abnormal and truncated splice form of SCN5A in heart failure. . |
Accessions | ENST00000526754.5 [P49756-2] ENST00000527432.5 [P49756-1] E9PQU5 ENST00000531500.5 H0YE46 L8EB35 E9PSE8 ENST00000261973.12 [P49756-1] P49756 ENST00000532192.1 ENST00000525321.5 [P49756-3] ENST00000525161.5 ENST00000528081.5 [P49756-4] |